NASDAQ:OTLK

Outlook Therapeutics Stock News

Healthcare > Biotechnology

Buy OTLK

*Your capital is at risk

$0.98

-0.0634 (-6.10%)

At Close: Jul 31, 2026

Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

09:15am, Wednesday, 08'th Jan 2025

Jedd Comiskey, Senior Vice President, Head of Europe, highlights the recent NICE recommendation of LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD

Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

08:05am, Friday, 27'th Dec 2024

ISELIN, N.J., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom ea

Outlook Therapeutics® Streamlines Operations

04:30pm, Friday, 13'th Dec 2024

ISELIN, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom ea

Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

08:05am, Wednesday, 04'th Dec 2024

First positive reimbursement decision worldwide for LYTENAVA™; First launch anticipated in H1 2025 LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment

Outlook Therapeutics® Announces Executive Leadership Transition

04:30pm, Tuesday, 03'rd Dec 2024

ISELIN, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom ea

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Outlook Therapeutics, Inc. - OTLK

02:31pm, Monday, 02'nd Dec 2024

NEW YORK , Dec. 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Outlook Therapeutics, Inc. ("Outlook" or the "Company") (NASDAQ: OTLK). Such investors are

OTLK Stock Falls on Failure to Meet Non-Inferiority Goal in AMD Study

11:31am, Thursday, 28'th Nov 2024

Outlook Therapeutics stock tanks 65% as ONS-5010 fails to meet the pre-specified non-inferiority endpoint at week 8 in the 90-day NORSE EIGHT study for wet AMD.

Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?

09:27am, Wednesday, 27'th Nov 2024

Outlook Therapeutics Inc. OTLK revealed preliminary topline results of NORSE EIGHT, the second of two clinical trials evaluating ONS-5010 in wet AMD patients.

Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial

06:50am, Wednesday, 27'th Nov 2024

ISELIN, N.J., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom ea

Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference

08:05am, Wednesday, 06'th Nov 2024

Live fireside chat with CEO, Russ Trenary, on November 12th at 2:30 PM ET Live fireside chat with CEO, Russ Trenary, on November 12th at 2:30 PM ET

OUTLOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating Outlook Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

09:00pm, Friday, 11'th Oct 2024

NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Outlook Therapeutics, Inc. (NASD

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by